Yong Li

Director of Cancer Reserach Laboratory and Principal Scientific Officer
Conjoint Professor

Dr Li is the Professor (Conjoint) in the Faculty of Medicine, UNSW Sydney; a Principal Scientific Officer at St George Hospital,  the South Eastern Sydney Local Health District (SESLHD); and Director of Cancer Research Laboratory at Cancer Care Centre. He is an established cancer researcher, with expertise in cancer biomarker discovery, cancer biology, radiation biology, targeted cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014.

Professor Li obtained his Bachelor of Medicine (B.M) degree in 1987 and Master of Science (MSc) degree in 1992 from the Henan Medical University, China. He obtained his PhD. degree in Faculty of Medicine, University of New South Wales (UNSW), Sydney, Australia, in 2000.  After two years of Postdoctoral study at UNSW, he was awarded the US Department Defence Prostate Cancer Research New Investigate Award in 2003 and then became an independent investigator.

Professor Li has a career total of 120 publications in peer-reviewed journals (3400 Scopus citations, 5500 google citations) since 1999.  His publications include the high impact journals, such as “Blood”, “Journal of Biological Chemistry”, “Clinical Cancer Research”, “Medicinal Research Reviews”, “Cancer and Metastasis Reviews”, “British Journal of Cancer” and “International Journal of Radiation Oncology, Biology, Physics”, “Theranostics” and "Advanced Materials". He is the senior/corresponding author in most of his publications. Ninety three conference abstracts have been presented at international and national conferences. His Scopus h-index is 36 and Google i10 index is 80.

Professor Li has attracted 7.2 million AU$ from different funding sources including NHMRC, ARC, US Department Defence, Cancer Institute NSW, and Prostate Cancer Foundation of Australia and Prostate and Breast Cancer Foundation (PBCF) as the principal investigator. Noticeably, he was awarded the best Biomedical Research Award-NHMRC Achievement Award in 2010. He currently serves on the Associate Editor of World Journal of Cancer Research (USA), and on the editorial board of the Open Biomarker Journal (USA).

Professor Li has supervised 12 PhD students as the principal supervisor (7) or co-supervisor (3). He has supervised 7 PhD students to completion. His PhD students have published in leading international peer-reviewed journals (25 papers) and presented at national and international conferences (42). His PhD students have been awarded 12 travel grants, 3 international scholarships and 3 UNSW research excellence awards.

He is an active member of American Association for Cancer Research (AACR) (USA), Chemistry in Cancer Research (USA), Cancer Metastasis Society (USA), International Cancer Microenvironment Society (USA), Australian Society of Medical Research, and Australian Prostate Cancer Collaboration as well as Member of postgraduate review committee at St George Clinical School. He is the President of Australian Association of Chinese Biomedical Scientists (AACBS) since 2015. He is an adjunct Professor in  Zhengzhou University, China since 2018.

Research Interests:

His current interest research areas include: a) To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression (prostate and breast cancer) uisng liquid biopsy and exosomes; b). To investigate the mechanisms of prostate and breast cancer metastasis and chemo/radio-resistance associated with tumour microenvironment,cancer stem cells and EMT and signalling pathways; c): To use targeted cancer therapy and combination therapy to control micrometastatic prostate cancer, bresat cancer and ovarian cancer.

Broad Research Areas:
Cancer, Proteomics, Cancer Stem Cells, Radiation Biology, Cancer Biology, Urology, Cancer biochemistry,

Qualifications:
BM, MSc, MD, PhD

Society Memberships & Professional Activities:
American Association for Cancer Research, Member of Chemistry in Cancer Research, USA, Member of Cancer Metastasis Society, USA, Australian Society of Medical Research, Fellow of the Cancer Institute NSW, Genitourinary Oncology Group, Australian Prostate Cancer Collaboration, Prostate Cancer Foundation of Australia, Cure Cancer Australia FoundationTeaching & Supervision

Specific Research Keywords:
Prostate cancer, Breast cancer, Ovarian Cancer, Cancer stem cell, Metastasis, Biomarker, Radiation treatment, Combination therapy, Radioresistance, Chemoresistance, Animal model, Liquid biopsy, Oncology, Exosome

Journal articles
add
Wang J; Ni J; Beretov J; Thompson J; Graham P; Li Y, 2020, 'Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer', Critical Reviews in Oncology/Hematology, vol. 145, pp. 102860 - 102860, http://dx.doi.org/10.1016/j.critrevonc.2019.102860
2020
Pang B; Zhu Y; Ni J; Thompson J; Malouf D; Bucci J; Graham P; Li Y, 2020, 'Extracellular vesicles: The next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis', Theranostics, vol. 10, pp. 2309 - 2326, http://dx.doi.org/10.7150/thno.39486
2020
Tran PHL; Xiang D; Nguyen TNG; Tran TTD; Chen Q; Yin W; Zhang Y; Kong L; Duan A; Chen K; Sun M; Li Y; Hou Y; Zhu Y; Ma Y; Jiang G; Duan W, 2020, 'Aptamer-guided extracellular vesicle theranostics in oncology', Theranostics, vol. 10, pp. 3849 - 3866, http://dx.doi.org/10.7150/thno.39706
2020
Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y, 2020, 'CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo', Experimental Cell Research, vol. 388, pp. 111850 - 111850, http://dx.doi.org/10.1016/j.yexcr.2020.111850
2020
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y, 2019, 'Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression', BMC Cancer, vol. 19, http://dx.doi.org/10.1186/s12885-019-5824-9
2019
Tsao T; Beretov J; Ni J; Bai X; Bucci J; Graham P; Li Y, 2019, 'Cancer stem cells in prostate cancer radioresistance', Cancer Letters, vol. 465, pp. 94 - 104, http://dx.doi.org/10.1016/j.canlet.2019.08.020
2019
Ni J; Bucci J; Malouf D; Knox M; Graham P; Li Y, 2019, 'Exosomes in Cancer Radioresistance', Frontiers in Oncology, vol. 9, http://dx.doi.org/10.3389/fonc.2019.00869
2019
Tran PHL; Xiang D; Tran TTD; Yin W; Zhang Y; Kong L; Chen K; Sun M; Li Y; Hou Y; Zhu Y; Duan W, 2019, 'Exosomes and Nanoengineering: A Match Made for Precision Therapeutics', Advanced Materials, http://dx.doi.org/10.1002/adma.201904040
2019
Ni J; Bongers A; Chamoli U; Bucci J; Graham P; Li Y, 2019, 'In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer', Cancer Control, vol. 26, pp. 1073274819846590, http://dx.doi.org/10.1177/1073274819846590
2019
Feng X; Bai X; Ni J; Wasinger VC; Beretov J; Zhu Y; Graham P; Li Y, 2019, 'CHTOP in chemoresistant epithelial ovarian cancer: A novel and potential therapeutic target', Frontiers in Oncology, vol. 9, http://dx.doi.org/10.3389/fonc.2019.00557
2019
Chang L; Ni J; Zhu Y; Pang B; Graham P; Zhang H; Li Y, 2019, 'Liquid biopsy in ovarian cancer: Recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression', Theranostics, vol. 9, pp. 4130 - 4140, http://dx.doi.org/10.7150/thno.34692
2019
Wang T; Yin W; AlShamaileh H; Zhang Y; Tran PHL; Nguyen TNG; Li Y; Chen K; Sun M; Hou Y; Zhang W; Zhao Q; Chen C; Zhang PZ; Duan W, 2019, 'A Detailed Protein-SELEX Protocol Allowing Visual Assessments of Individual Steps for a High Success Rate', Human Gene Therapy Methods, vol. 30, pp. 1 - 16, http://dx.doi.org/10.1089/hgtb.2018.237
2019
Bai X; Ni J; Beretov J; Graham P; Li Y, 2018, 'Cancer stem cell in breast cancer therapeutic resistance', Cancer Treatment Reviews, vol. 69, pp. 152 - 163, http://dx.doi.org/10.1016/j.ctrv.2018.07.004
2018
Ni J; Cozzi P; Beretov J; Duan W; Bucci J; Graham P; Li Y, 2018, 'Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo', BMC Cancer, vol. 18, pp. 1092, http://dx.doi.org/10.1186/s12885-018-5010-5
2018
Xiang D; Shigdar S; Bean AG; Bruce M; Yang W; Mathesh M; Wang T; Yin W; Tran PHL; Shamaileh HA; Barrero RA; Zhang PZ; Li Y; Kong L; Liu K; Zhou SF; Hou Y; He A; Duan W, 2017, 'Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery', Theranostics, vol. 7, http://dx.doi.org/10.7150/thno.20168
2017
Alshamaileh H; Wang T; Xiang D; Yin W; Tran PHL; Barrero RA; Zhang PZ; Li Y; Kong L; Liu K; Zhou SF; Hou Y; Shigdar S; Duan W, 2017, 'Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/s41598-017-05859-z
2017
Ni J; Bucci J; Chang L; Malouf D; Graham P; Li Y, 2017, 'Targeting microRNAs in prostate cancer radiotherapy', Theranostics, vol. 7, pp. 3243 - 3259, http://dx.doi.org/10.7150/thno.19934
2017
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y, 2017, 'Urinary biomarkers in prostate cancer detection and monitoring progression', Critical Reviews in Oncology/Hematology, vol. 118, pp. 15 - 26, http://dx.doi.org/10.1016/j.critrevonc.2017.08.002
2017
Chang L; Ni J; Beretov J; Wasinger VC; Hao J; Bucci J; Malouf D; Gillatt D; Graham PH; Li Y, 2017, 'Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/srep41834
2017
Chang L; Graham P; Hao J; Ni J; Deng J; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Cancer stem cells and signaling pathways in radioresistance', Oncotarget, vol. 7, pp. 11002 - 11017, http://dx.doi.org/10.18632/oncotarget.6760
2016
You J; Willcox M; Fitzgerald A; Schiller B; Cozzi PJ; Russell PJ; Walsh BJ; Wasinger VC; Graham PH; Li Y, 2016, 'Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling', Analytical Biochemistry, vol. 496, pp. 30 - 34, http://dx.doi.org/10.1016/j.ab.2015.12.006
2016
Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy', Oncotarget, vol. 7, pp. 74269 - 74285, http://dx.doi.org/10.18632/oncotarget.12368
2016
Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y, 2016, 'Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer', Oncotarget, vol. 7, pp. 55771 - 55788, http://dx.doi.org/10.18632/oncotarget.9908
2016
Ni J; Cozzi P; Hung T; Hao J; Graham PH; Li Y, 2016, 'Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique', Translational Oncology, vol. 9, pp. 41 - 45, http://dx.doi.org/10.1016/j.tranon.2015.11.011
2016
Deng J; Wang L; Ni J; Beretov J; Wasinger V; Wu D; Duan W; Graham P; Li Y, 2016, 'Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy', Expert Review of Proteomics, vol. 13, pp. 905 - 915, http://dx.doi.org/10.1080/14789450.2016.1233065
2016
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y, 2015, 'Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance', Critical Reviews in Oncology/Hematology, vol. 96, pp. 507 - 517, http://dx.doi.org/10.1016/j.critrevonc.2015.07.005
2015
Xiang D; Zheng C; Zhou SF; Qiao S; Tran PHL; Pu C; Li Y; Kong L; Kouzani AZ; Lin J; Liu K; Li L; Shigdar S; Duan W, 2015, 'Superior performance of aptamer in tumor penetration over antibody: Implication of aptamer-based theranostics in solid tumors', Theranostics, vol. 5, pp. 1083 - 1097, http://dx.doi.org/10.7150/thno.11711
2015
Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y, 2015, 'Proteomics discovery of radioresistant cancer biomarkers for radiotherapy', Cancer Letters, vol. 369, pp. 289 - 297, http://dx.doi.org/10.1016/j.canlet.2015.09.013
2015
Xiang D; Shigdar S; Qiao G; Zhou SF; Li Y; Wei MQ; Qiao L; Al Shamaileh H; Zhu Y; Zheng C; Pu C; Duan W, 2015, 'Aptamer-mediated cancer gene therapy', Current Gene Therapy, vol. 15, pp. 109 - 119, http://dx.doi.org/10.2174/1566523214666141224095105
2015
Beretov J; Wasinger VC; Millar EKA; Schwartz P; Graham PH; Li Y, 2015, 'Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0141876
2015
Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Al Shamaileh H; Yin W; Zhou SF; Zhao X; Duan W, 2015, 'Cancer stem cell targeted therapy: Progress amid controversies', Oncotarget, vol. 6, pp. 44191 - 44206, http://dx.doi.org/10.18632/oncotarget.6176
2015
Chang L; Graham PH; Hao J; Jie N; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 34, pp. S50 - S50, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000341276000182&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Beretov J; Wasinger VC; Graham PH; Millar EK; Kearsley JH; Li Y, 2014, 'Proteomics for breast cancer urine biomarkers', Advances in Clinical Chemistry, vol. 63, pp. 123 - 167, http://dx.doi.org/10.1016/B978-0-12-800094-6.00004-2
2014
Beretov J; Wasinger VC; Schwartz P; Graham PH; Li Y, 2014, 'A standardized and reproducible urine preparation protocol for cancer biomarkers discovery.', Biomark Cancer, vol. 6, pp. 21 - 27, http://dx.doi.org/10.4137/BIC.S17991
2014
O'Connor ML; Xiang D; Shigdar S; Macdonald J; Li Y; Wang T; Pu C; Wang Z; Qiao L; Duan W, 2014, 'Cancer stem cells: A contentious hypothesis now moving forward', Cancer Letters, vol. 344, pp. 180 - 187, http://dx.doi.org/10.1016/j.canlet.2013.11.012
2014
Shigdar S; O'Connor M; Lin J; Wang T; Xiang D; Duan W; Li Y; Bhattacharya S; Pu C; Kong L; Wei MQ; Zhu Y; Zhou S, 2014, 'Inflammation and cancer stem cells', Cancer Letters, vol. 345, pp. 271 - 278, http://dx.doi.org/10.1016/j.canlet.2013.07.031
2014
Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y, 2014, 'CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance', The Prostate, vol. 74, pp. 602 - 617, http://dx.doi.org/10.1002/pros.22775
2014
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways', Cell Death and Disease, vol. 5, http://dx.doi.org/10.1038/cddis.2014.415
2014
Chang L; Graham PH; Hao J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy', Cancer and Metastasis Reviews, vol. 33, pp. 469 - 496, http://dx.doi.org/10.1007/s10555-014-9493-5
2014
Ni J; Cozzi P; Hao J; Duan W; Graham P; Kearsley J; Li Y, 2014, 'Cancer stem cells in prostate cancer chemoresistance', Current Cancer Drug Targets, vol. 14, pp. 225 - 240, http://dx.doi.org/10.2174/1568009614666140328152459
2014
Lei C; Wasinger V; Graham P; Hao J; Ni J; Beretov J; Bucci J; Cozzi P; Kearsley J; Li Y, 2014, 'THE USE OF LABEL-FREE LC-MS/MS APPROACH TO IDENTIFY SIGNALING PATHWAYS ASSOCIATED WITH PROSTATE CANCER RADIORESISTANCE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 10, pp. 130 - 130, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Xiao W; Graham PH; Hao J; Chang L; Ni J; Power CA; Dong Q; Kearsley JH; Li Y, 2013, 'Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0074253
2013
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2013, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway', International Journal of Biochemistry and Cell Biology, vol. 45, pp. 2736 - 2748, http://dx.doi.org/10.1016/j.biocel.2013.09.008
2013
Chang L; Graham P; Hao J; Ni J; Bucci J; Cozzi P; Kearseley J; Li Y, 2013, 'PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.', MOLECULAR CANCER THERAPEUTICS, vol. 12, http://dx.doi.org/10.1158/1535-7163.TARG-13-A283
2013
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kersley JH; Li Y, 2013, 'Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro', Cancer Letters, vol. 1, pp. 17 - 26, http://dx.doi.org/10.1016/j.canlet.2012.08.035
2013
You J; Willcox MD; Madigan MC; Wasinger V; Schiller B; Walsh BJ; Graham PH; Kearsley JH; Li Y, 2013, 'Tear Fluid Protein Biomarkers', Advances in Clinical Chemistry, vol. 62, pp. 151 - 196, http://dx.doi.org/10.1016/B978-0-12-800096-0.00004-4
2013
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2013, 'Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance', Cell Death and Disease, vol. 4, http://dx.doi.org/10.1038/cddis.2013.407
2013
Shigdar S; Qian C; Lv LX; Pu C; Li Y; Li LH; Marappan M; Lin J; Wang L; Duan W, 2013, 'The Use of Sensitive Chemical Antibodies for Diagnosis:Detection of Low Levels of Epcam in Breast Cancer', PLoS One, vol. 8, pp. Article numbere57613, http://dx.doi.org/10.1371/journal.pone.0057613
2013
Shigdar S; Qiao L; Zhou S; Xiang D; Wang T; Li Y; Lim L; Kong L; Li LH; Duan W, 2013, 'RNA aptamers targeting cancer stem cell marker CD133', Cancer Letters, vol. 330, pp. 84 - 95, http://dx.doi.org/10.1016/j.canlet.2012.11.032
2013
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y, 2013, 'The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression', Cancer and Metastasis Reviews, vol. 32, pp. 535 - 551, http://dx.doi.org/10.1007/s10555-013-9423-y
2013
Hao J; Ni J; Cozzi PJ; Graham PH; Bucci J; Kearsley J; Li Y, 2013, 'The CD44 Isoforms in Prostate Cancer Metastasis and progression', World Journal of Cancer Research, vol. 1, pp. 3 - 14, http://dx.doi.org/10.1166/wjcr.2013.1009
2013
O'Connor ML; Xiang D; Shigdar S; Macdonald J; Wang T; Duan W; Li Y; Pu C; Wang Z; Qiao L, 2013, 'Cancer stem cells: A contentious hypothesis now moving forward', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2013.11.012
2013
Shigdar S; O'Connor M; Lin J; Wang T; Xiang D; Duan W; Li Y; Bhattacharya S; Pu C; Kong L; Wei MQ; Zhu Y; Zhou S, 2013, 'Inflammation and cancer stem cells', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2013.07.031
2013
Ni J; Cozzi PJ; Duan W; Shigdar S; Graham PH; Kearsley J; Li Y, 2012, 'Role of the EpCAM (CD326) in prostate cancer metastasis and progression.', Cancer and Metastasis Reviews, vol. 31, pp. 779 - 791, http://dx.doi.org/10.1007/s10555-012-9389-1
2012
Hao J; Madigan MC; Khatri A; Power C; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley J; Li Y, 2012, 'In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147', PLoS One, vol. 7, pp. 1 - 14, http://dx.doi.org/10.1371/journal.pone.0040716
2012
Shigdar S; Lin J; Li Y; Yang C; Wei M; Zhu Y; Liu H; Duan W, 2012, 'Cancer stem cell targeting: The next generation of cancer therapy and molecular imaging', Therapeutic Delivery, vol. 3, pp. 227 - 244, http://dx.doi.org/10.4155/tde.11.148
2012
Xiao W; Graham PH; Power C; Hao J; Kearsley J; Li Y, 2012, 'CD44 is a biomarker associated with human prostate cancer radiation sensitivity', Clinical and Experimental Metastasis, vol. 29, pp. 1 - 9, http://dx.doi.org/10.1007/s10585-011-9423-7
2012
Wang L; Chen H; Liu F; Madigan MC; Power C; Hao J; Patterson K; Pourgholami MH; O Brien P; Perkins A; Li Y, 2011, 'Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer', Cancer Letters, vol. 300, pp. 122 - 133, http://dx.doi.org/10.1016/j.canlet.2010.09.013
2011
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins A; Kearsley J; Li Y, 2011, 'Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model.', PLoS One, vol. 6(9), pp. 1 - 13, http://dx.doi.org/10.1371/journal.pone.0024405
2011
Li Y; Cozzi PJ; Russell P, 2010, 'Promising tumor-associated antigens for future prostate cancer therapy', Medicinal Research Reviews, vol. 30, pp. 67 - 101, http://dx.doi.org/10.1002/med.20165
2010
You J; Fitzgerald A; Cozzi PJ; Zhao Z; Graham PH; Russell PJ; Walsh B; Willcox MD; Ling Z; Wasinger VC; Li Y, 2010, 'Post-translation modification of proteins in tears', Electrophoresis, vol. 31, pp. 1853 - 1861, http://dx.doi.org/10.1002/elps.200900755
2010
You J; Cozzi PJ; Walsh B; Willcox MD; Kearsley J; Russell PJ; Li Y, 2010, 'Innovative biomarkers for prostate cancer early diagnosis and progression', Critical Reviews in Oncology Hematology, vol. 73, pp. 10 - 22, http://dx.doi.org/10.1016/j.critrevonc.2009.02.007
2010
Chen H; Wang L; Beretov J; Hao J; Xiao W; Li Y, 2010, 'Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression', Clinical and Experimental Metastasis, vol. 27, pp. 557 - 569, http://dx.doi.org/10.1007/s10585-010-9345-9
2010
Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y, 2010, 'CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer', Current Cancer Drug Targets, vol. 10, pp. 287 - 306, http://dx.doi.org/10.2174/156800910791190193
2010
Hao JL; Chen H; Madigan MC; Cozzi PJ; Beretov J; Xiao W; Delprado W; Russell PJ; Li Y, 2010, 'Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.', British Journal of Cancer, vol. 103, pp. 1008 - 1018, http://dx.doi.org/10.1038/sj.bjc.6605839
2010
Li Y; Cozzi PJ, 2010, 'Angiogenesis as a strategic target for prostate cancer therapy', Medicinal Research Reviews, vol. 30, pp. 23 - 66, http://dx.doi.org/10.1002/med.20161
2010
Li Y; Song YE; Rizvi SM; Power C; Beretov J; Raja C; Cozzi PJ; Morgenstern A; Apostolidis C; Allen BJ; Russell PJ, 2009, 'Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By (213)Bilabeled Multiple Targeted alpha Radioimmunoconjugates', Clinical Cancer Research, vol. 15, pp. 865 - 875, http://dx.doi.org/10.1158/1078-0432.CCR-08-1203
2009
Chen H; Hao J; Wang L; Li Y, 2009, 'Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression', British Journal of Cancer, vol. 101, pp. 432 - 440, http://dx.doi.org/10.1038/sj.bjc.6605185
2009
Madigan M; Kingsley E; Paul C; Delprado W; Russell P; Li Y, 2009, 'The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression', CLINICAL & EXPERIMENTAL METASTASIS, vol. 26, pp. 898 - 898, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000271722300160&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Wang LL; Madigan MC; Chen H; Liu F; Patterson K; Beretov J; O Brien P; Li Y, 2009, 'Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients', Gynecologic Oncology, vol. 114, pp. 265 - 272, http://dx.doi.org/10.1016/j.ygyno.2009.04.031
2009
Rizvi SM; Qu CF; Raja C; Yuen J; Li Y; Morgenstern A; Apostolidis C; Allen BJ; Song YE, 2008, 'The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy', Physics in Medicine and Biology, vol. 53, pp. 319 - 328, http://dx.doi.org/10.1088/0031-9155/53/2/001
2008
Madigan MC; Kingsley EA; Cozzi PJ; Delprado W; Russell PJ; Li Y, 2008, 'The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression', Cancer Immunology and Immunotherapy, vol. 57, pp. 1367 - 1379, http://dx.doi.org/10.1007/s00262-008-0473-x
2008
Kearsley J; Cozzi PJ; Li Y, 2008, 'Overview of Tumor-Associated Antigens (TAAs) as potential Therapeutic Targets for prostate Cancer Therapy', Current Cancer Therapy Reviews, vol. 4, pp. 271 - 284, http://dx.doi.org/10.2174/157339408786413371
2008
Li Y; Cozzi PJ, 2007, 'Targeting uPA/uPAR in prostate cancer', Cancer Treatment Reviews, vol. 33, pp. 521 - 527, http://dx.doi.org/10.1016/j.ctrv.2007.06.003
2007
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins A; Li Y, 2007, 'Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance', Gynecologic Oncology, vol. 105, pp. 695 - 702, http://dx.doi.org/10.1016/j.ygyno.2007.02.004
2007
Li Y; Cozzi PJ, 2007, 'MUC1 is a promising therapeutic target for prostate cancer therapy', Current Cancer Drug Targets, vol. 7, pp. 259 - 271, http://dx.doi.org/10.2174/156800907780618338
2007
Wang J; Rizvi SM; Madigan MC; Cozzi PJ; Power C; Qu CF; Morgenstern A; Apostolidis C; Russell PJ; Allen BJ; Li Y, 2006, 'Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.', Prostate, vol. 66, pp. 1753 - 1767, http://dx.doi.org/10.1002/pros.20502
2006
Wang JQ; Abbas Rizvi SM; Madigan MC; Cozzi PJ; Morgenstern A; Qu CF; Apostolidis C; Russell PJ; Allen BJ; Li Y, 2006, 'Control of prostate cancer spheroid growth using (213)Bi-labeled multiple targeted alpha radioimmunoconjugates', Prostate, vol. 66, pp. 1753 - 1767
2006
Cozzi PJ; Wang JQ; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y, 2006, 'Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer', Human Pathology, vol. 37, pp. 1442 - 1451, http://dx.doi.org/10.1016/j.humpath.2006.05.002
2006
Song YE; Qu CF; Rizvi SM; Li Y; Robertson G; Raja C; Morgenstern A; Apostolidis C; Perkins A; Allen BJ, 2006, 'Cytoxicity of PA12, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters', Cancer Letters, vol. 234, pp. 176 - 183, http://dx.doi.org/10.1016/j.canlet.2005.03.060
2006
Rizvi SM; Li Y; Song YE; Qu CF; Raja C; Morgenstern A; Apostollidis C; Allen BJ, 2006, 'Preclinical studies of Bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model', Cancer Biology and Therapy, vol. 5, pp. 386 - 393
2006
Li Y; Wang JQ; Rizvi SM; Conway RM; Billson FA; Allen BJ; Madigan MC, 2005, 'In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells', Investigative Ophthalmology and Visual Science, vol. 46, pp. 4365 - 4371, http://dx.doi.org/10.1167/iovs.05-0559
2005
Nielsen A; Scarlett CJ; Samra JS; Gill A; Li Y; Allen BJ; Smith RC, 2005, 'Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 20, pp. 256 - 263, http://dx.doi.org/10.1111/j.1440-1746.2004.03531.x
2005
Qu CF; Li Y; Rizvi SM; Raja C; Smith RC; Morgenstern A; Apostolidis C; Allen BJ; Song YE, 2005, 'Pre-clinical study of Bi-213 labeled PAI2 for the control of micrometastatic pancreatic cancer', Clinical and Experimental Metastasis, vol. 22, pp. 575 - 586, http://dx.doi.org/10.1007/s10585-005-5788-9
2005
Zhang D; Li Y; Rizvi SM; Qu CF; Kearsley J; Allen BJ, 2005, 'Cytotoxicity of breast cancer cells overexpressing HER2/neu by(213)Bi-Herceptin radioimmunoconjugate', Cancer Letters, vol. 218, pp. 181 - 190, http://dx.doi.org/10.1016/j.canlet.2004.07.050
2005
Qu CF; Song YE; Rizvi SM; Li Y; Smith RC; Perkins A; Morgenstern A; Brechbiel M; Allen BJ, 2005, 'In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using Bi-213-CHX.A`-C595', Cancer Biology and Therapy, vol. 4, pp. 848 - 853
2005
Qu CF; Songl YJ; Rizvi SMA; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ, 2005, 'In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.', Cancer biology & therapy, vol. 4, pp. 848 - 853, http://dx.doi.org/10.4161/cbt.4.8.1892
2005
Cozzi PJ; Wang J; Delprado W; Perkins A; Allen BJ; Russell PJ; Li Y, 2005, 'MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer', Clinical and Experimental Metastasis, vol. 22, pp. 565 - 573, http://dx.doi.org/10.1007/s10585-005-5376-z
2005
Allen BJ; Raja C; Rizvi SM; Tsui WW; Li Y; Graham PH; Thompson J; Reisfeld RA; Kearsley J; Morgenstern A; Apostolidis C, 2005, 'Intralesional targeted alpha therapy for metastatic melanoma', Cancer Biology and Therapy, vol. 4, pp. 1318 - 1324, http://dx.doi.org/10.4161/cbt.4.12.2251
2005
Cozzi PJ; Rizvi SM; Wang J; Qu CF; Allen BJ; Li Y, 2005, 'Expression of membrane-bound uPA in human prostate cancer cells for in vitro and in vivo targeted alpha therapy using 213Bi-PAI2 alpha emitting radioconjugate', British Journal of Urology, vol. 95, pp. 16 - 17, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000236061300075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2005
Qu CF; Song YE; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins A; Apostolidis C; Allen BJ, 2004, 'MUC-1 expression in primary and metastatic [ancreatic cancer cells for in vitro treatment by 213 Bi-C595 radioimmunoconjugate', British Journal of Cancer, vol. 91, pp. 2086 - 2093, http://dx.doi.org/10.1038/sj.bjc.6602232
2004
Allen BJ; Raja C; Rizvi SM; Li Y; Tsui WW; Zhang DY; Song YE; Qu CF; Kearsley J; Graham PH; Thompson J, 2004, 'Targeted alpha therapy for cancer', Physics in Medicine and Biology, vol. 49, pp. 3703 - 3712, http://dx.doi.org/10.1088/0031-9155/49/16/016
2004
Li Y; Russell PJ; Allen BJ, 2004, 'Targeted alpha-therapy for control of micrometastatic prostate cancer', Expert Review of Anticancer Therapy, vol. 4, pp. 459 - 468, http://dx.doi.org/10.1586/14737140.4.3.459
2004
Li Y; Russell PJ; Allen BJ, 2004, 'Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate', Cancer Letters, vol. 205, pp. 161 - 171, http://dx.doi.org/10.1016/j.canlet.2003.10.035
2004
Russell PJ; Ow KT; Tam P; Juarez J; Kingsley EA; Li Y; Cozzi PJ; Qu CF; Martiniello-Wilks R, 2004, 'Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer', Cancer Immunology and Immunotherapy, vol. 53, pp. 995 - 1004, http://dx.doi.org/10.1007/s00262-004-0527-7
2004
Li Y; Rizvi SM; Blair JM; Cozzi PJ; Chang QF; Kim OT; Tam P; Perkins A; Russell PJ; Allen BJ, 2004, 'Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines for In Vitro Multiple-Targetes A-Therapy with 21Bi-Conjugates', International Journal of Radiation Oncology and Biology Physics, vol. 60, pp. 896 - 908, http://dx.doi.org/10.1016/j.ijrobp.2004.04.035
2004
Li Y; Madigan MC; Conway RM; Billson FA; Crouch RL; Allen BJ, 2003, 'Human uveal melanoma expresses NG2 immunoreactivity', British Journal of Ophthalmology, vol. 87, pp. 629 - 632, http://dx.doi.org/10.1136/bjo.87.5.629
2003
Li L; Li Y; Krilis S; Qi JC; Moore CH; Madigan MC; Katsoulotos GP, 2003, 'An antibody raised against in-vitro-derived human mast cells identifies mature mast cells and a population of cells that are Fc...., Tryptase, and chymase in a variety of human tissues', Journal of Histochemistry and Cytochemistry, vol. 51, pp. 643 - 653, http://dx.doi.org/10.1177/002215540305100510
2003
Rizvi SM; Li Y; Raja C; Allen BJ, 2003, 'In vitro and preclinical testing of Bi-213 labeled antimelanoma monoclonal antibody 9.2.27', Abstracts of Papers of the American Chemical Society, vol. 225, pp. U261 - U261, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000187918001337&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2003
Allen BJ; Tian Z; Rizvi SMA; Li Y; Ranson M, 2003, 'Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2', British Journal of Cancer, vol. 88, pp. 944 - 950, http://dx.doi.org/10.1038/sj.bjc.6600838
2003
Li Y; Rizvi SMA; Ranson M; Allen BJ, 2002, 'Bi-213-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model', BRITISH JOURNAL OF CANCER, vol. 86, pp. 1197 - 1203, http://dx.doi.org/10.1038/sj/bjc/6600179
2002
Li Y; Tian Z; Rizvi SMA; Bander NH; Allen BJ, 2002, 'In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen', Prostate Cancer and Prostatic Diseases, vol. 5, pp. 36 - 46, http://dx.doi.org/10.1038/sj.pcan.4500543
2002
Allen BJ; Rizvi S; Li Y; Tian Z; Ranson M, 2001, 'In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers', Critical Reviews in Oncology/Hematology, vol. 39, pp. 139 - 146, http://dx.doi.org/10.1016/S1040-8428(01)00113-5
2001
Allen BJ; Tian Z; Li Y; Andronicos NJ; Rizvi S; Ranson M, 2001, 'In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labeled-plasminogen activator inhibitor type 2', EUROPEAN JOURNAL OF NUCLEAR MEDICINE, vol. 28, pp. 1191 - 1191, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000170528300888&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2001
Li Y; Li L; Wadley RB; Reddel SW; Qi JC; Archis CA; Collins AM; Clarke E; Cooley MA; Kouts S; Naif H; Alali M; Cunningham AL; Wong GW; Stevens RL; Krilis S, 2001, 'Mast cell/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5 and CXCR4', Blood, vol. 97, pp. 3484 - 3490, http://dx.doi.org/10.1182/blood.V97.11.3484
2001
Li Y; Li L; Wadley R; Reddel S; Qi J; Archis C; Collins A; Clark E; Cooley M; Kouts S; Hassan N; Mohammed A; Cunningham A; Wong G; Stevens R; Krilis S, 2000, 'Identification of a novel population of mast cells/basophils in human periphal blood of allergic patients which is HIV-1 susceptible due to its surface expression of CD4, CCR5, and CXCR4', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 105, pp. S86 - S87, http://dx.doi.org/10.1016/S0091-6749(00)90690-0
2000
Li L; Li Y; Krilis SA, 1999, 'Monoclonal antibodies recognizing antigens expressed in human mast cells and their progenitors.', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 103, pp. S43 - S43, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000078509000170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1999
Li L; Li Y; Krilis SA, 1999, 'Monoclonal antibodies recognizing antigens expressed in human mast cells and their progenitors', FASEB JOURNAL, vol. 13, pp. A337 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000082033301949&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1999
Li L; Li Y; Reddel SW; Cherrian M; Friend DS; Stevens RL; Krilis SA, 1999, 'Cells that have features of both mast cells and basophils in the peripheral blood of allergy, asthma, and drug reactive', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 103, pp. S43 - S43, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000078509000169&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1999
Wong GW; Tang Y; E F; Sali A; Li L; Li YW; Huang C; Friend DS; Krilis S; Stevens RL, 1999, 'Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension', The Journal of Biological Chemistry, vol. 274, pp. 30784 - 30793, http://dx.doi.org/10.1074/jbc.274.43.30784
1999
Li L; Li Y; Reddel SW; Cherrian M; Friend DS; Stevens RL; Krilis S, 1998, 'Identification of Basophilic Cells that Express Mast Cell Granule Proteases in the Peripheral Blood of Asthma, Allergy, and Drug-Reactive Patients', Journal of Immunology, vol. 161, pp. 5079 - 5086
1998
Conference Papers
add
Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2018, 'Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Chicago, IL, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Chicago, IL, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-1999
2018
Ni J; Cozzi P; Beretov J; Deng J; Bucci J; Graham P; Li Y, 2017, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo/radio-resistance in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-2833
2017
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways in vitro', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, San Diego, CA, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), San Diego, CA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-4005
2014
You J; Fitzgerald A; Cozzi PJ; Zhao Z; Russell PJ; Walsh B; Willcox MD; Li Y, 2008, 'Identification of the potential biomakers for prostate cancer from tears and sera using proteomic methods', in The 13th Annual Proteomics Symposium Erskine Mantra Resort, 13th Annual Proteomics Symposium Erskine Mantra Resort, Lorne , VIC, presented at 13th Annual Proteomics Symposium Erskine Mantra Resort, Lorne , VIC, 08 February 2008 - 10 February 2008
2008
Li Y; Liu WY, 2008, 'Backward probabilistic logic reasoning algorithm for decision problem with conditional event algebra on bayesian networks', in Proceedings of the 7th International Conference on Machine Learning and Cybernetics, ICMLC, pp. 1744 - 1749, http://dx.doi.org/10.1109/ICMLC.2008.4620687
2008
Li Y; Wang JQ; Rizvi SM; Cozzi PJ; Madigan MC; Power C; Russell PJ; Allen BJ, 2006, 'Control of DU 145 and LNCaP-LN3 prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates', in Annals of Oncology, Oxford Univ Press, Oxford, England, pp. 47 - 47, presented at Symposium on targeted anticancer therapies, Amsterdam, 16 March 2006 - 18 March 2006, http://dx.doi.org/10.1093/annonc/mdl921
2006
Li Y; Rizvi SMA; Wang J; Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJH; Allen BJ, 2004, 'Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines and Primary Prostate Cancer Sections for In Vitro Multiple Targeted Alpha Therapy with 213Bi-conjugates.', in Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines and Primary Prostate Cancer Sections for In Vitro Multiple Targeted Alpha Therapy with 213Bi-conjugates., 95th AACR annual meeting, presented at 95th AACR annual meeting, 27 March 2004 - 31 March 2004
2004
Li Y; Wang J; Zhang DY; Rizvi SMA; Lai K; Conway RM; Jager M; B illson FA; Allen BJ, 2004, 'In Vitro Targeting of NG2 antigen by 213Bi-9.2.27 radioimmunoconjugate induces cytotoxicity in human uveal melanoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, presented at XVI international congress of eye research, 29 August 2004 - 03 September 2004
2004
Qu CF; Li Y; Rizvi SMA; Allen B, 2003, 'In vitro cytotoxicity of alpha conjugates for human pancreatic cancer cell lines', in In vitro cytotoxicity of alpha conjugates for human pancreatic cancer cell lines, 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
2003
Rizvi SMA; Li Y; Allen BJ, 2003, 'Evaluation of preclinical single and multiple dose toxicity and efficacy of 213Bi-labeled plasminogen activator inhibitor 2 for breast and prostate cancer.', in Evaluation of preclinical single and multiple dose toxicity and efficacy of 213Bi-labeled plasminogen activator inhibitor 2 for breast and prostate cancer., 17 September 2003 - 22 September 2003
2003
Syed SMA; Li Y; Allen BJ, 2003, 'In vitro and in vivo targeted alpha therapy (TAT) of colorectal cancer using monoclonal antibodies c30 and 35A7', in In vitro and in vivo targeted alpha therapy (TAT) of colorectal cancer using monoclonal antibodies c30 and 35A7, 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
2003
Li Y; Syed SMA; Allen B, 2003, '213Bi-PAI2 conjugate selectively induced apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model', in 213Bi-PAI2 conjugate selectively induced apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model, 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
2003
Li Y; Cozzi PJ; Qu CF; Zhang D; Rizvi SMA; Raja C; Allen BJ, 2003, 'Targeted alpha therapy for human prostate cancer cell lines in vitro using -particle emitter (213Bi)-labeled Herceptin.', in Targeted alpha therapy for human prostate cancer cell lines in vitro using -particle emitter (213Bi)-labeled Herceptin., 12th International Congress of Radiation Research, presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
2003
Conference Abstracts
add
Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2017, 'Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, Singapore, SINGAPORE, Vol. 28, presented at ESMO Asia Congress, Singapore, SINGAPORE, 17 November 2017 - 19 November 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425626900265&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2017
Hao J; Graham P; Chang L; Ni J; Beretov J; Deng J; Bucci J; Cozzi P; Li Y, 2015, 'Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, Cairns, AUSTRALIA, Vol. 116, pp. 33 - 34, presented at 2nd Prostate Cancer World Congress (PCWC), Cairns, AUSTRALIA, 17 August 2015 - 21 August 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Deng J; Duan W; Graham P; Bucci J; Li Y, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, Cairns, AUSTRALIA, Vol. 116, pp. 31 - 31, presented at 2nd Prostate Cancer World Congress (PCWC), Cairns, AUSTRALIA, 17 August 2015 - 21 August 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Hao J; Graham PH; Chang L; Ni J; Wasinger V; Beretov J; Bucci J; Cozzi P; Li Y, 2015, 'Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2001
2015
Book Chapters
add
Beretov J; Wasinger V; Graham P; Millar E; Kearsley J; Li Y, 2014, 'Proteomic techniques to detect urinary biomarkers in breast cancer', in Makowski G (ed.), Advances in Clinical Chemistry, Elsevier, pp. 123 - 167, http://www.sciencedirect.com/science/bookseries/00652423/63/supp/C
2014
You J; Cozzi PJ; Fitzgerald A; Walsh B; Russell PJ; Willcox M; Graham P; Li Y, 2013, 'Tear as a source of protein biomarkers for human disease diagnosis and prognosis', in Makowski G (ed.), Tear as a source of protein biomarkers for human disease diagnosis and prognosis
2013
You J; Cozzi PJ; Fitzgerald A; Walsh B; Russell ; Willcox MD; Li Y, 2012, 'Prostate Cancer Biomarkers and the Emerging Proteomic Techniques Used in Biomarker Research', in Watanabe HS (ed.), Horizons in Cancer Research Vol 47, edn. First, Nova Science Publishers Inc, New York, pp. 1 - 36, https://www.novapublishers.com/catalog/product_info.php?products_id=27295
2012
Hao J; Madigan MC; Cozzi PJ; Kearsley J; Li Y; Hao J, 2011, 'Angiogenesis, Lymphangiogenesis and Vasculogenic Mimicry in Human Prostate Cancer Therapy', in Berhardt LV (ed.), Advances in Medicine and Biology, edn. Volume 38, Nova Science Publishers, Inc., New York, USA, pp. 49 - 90, https://www.novapublishers.com/catalog/product_info.php?products_id=32769
2011
Xiao W; Graham PH; Power C; Li Y, 2010, 'Biomarkers for radiosensitivity and radiosensitivity targets in prostate cancer', in Nguyen SD (ed.), Tumour Suppressors, Nova Science Publishers, USA, pp. 189 - 228
2010
Allen BJ; Li Y; Rizvi SM; Russell PJ, 2003, 'Targeted Alpha Therapy of Prostate Cancer', in Russell PJ (ed.), Prostrate Cancer Methods and Protocols, Humana Press, Totowa, new Jersey, pp. 333 - 357
2003
Li Y; Li L; Krilis S, 1997, 'Growth factors modulating human mast cell growth and function', in Seminars in Clinical Immunology, edn. Original, Edizioni Grafiche Mazzucchelli S.B.L., Italy, pp. 17 - 24
1997
Conference Presentations
add
Hao JL; Madigan MC; Cozzi PJ; Khatri A; Power CA; Beretov J; Kearsley J; Li Y; Hao J, 2012, 'CD44 and CD147 expression influence prostate cancer chemoresistance and metastasis', presented at The Australian Society for Medical Research (ASMR), Sydney, Australia, -
2012
Beretov J; Wasinger V; Graham PH; Kearsley J; Li Y, 2012, 'Identification of novel urine biomarkers from metastatic breast cancer patients using proteomic approaches.', presented at Asia Oceania Human Proteome Organization (AOHUPO) 6th Congress, China National Convention Center, Beijing, China, 05 May 2012 - 07 May 2012
2012
Li Y; Hao JL; Cozzi PJ; Kearsley J; Hao J, 2010, 'CD44 and CD147 in prostate cancer metastasis and chemoresistance', presented at Sixth International Symposium on Hormonal Oncogenesis, Tokyo, Japan, 12 September 2010 - 16 September 2010
2010
You J; Fitzgerald A; Cozzi PJ; Zhao Z; Russell PJ; Walsh B; Willcox MD; Graham PH; Li Y, 2010, 'Using proteomic approaches to identify potential biomarkers for prostate cancer in tears and serum', presented at 3rd Annual World Cancer Congress, Singapore, 22 June 2010 - 25 June 2010
2010
You J; Fitzgerald A; Cozzi PJ; Zhao Z; Graham PH; Russell PJ; Walsh B; Willcox MD; Wasinger VC; Li Y, 2010, 'Identification of potential biomarkers for prostate cancer in tears and serum using proteomic approaches', presented at HUPO-9th Annual World Congress, Sydney, Australia, 19 September 2010 - 23 September 2010
2010
You J; Fitzgerald A; Schiller S; Cozzi PJ; Walsh B; Willcox MD; Wasinger VC; Li Y, 2010, 'Identification of potential biomarkers for prostate cancer in tears and serum using proteomic approaches', presented at The Inaugural Biomarker Discovery Conference, Port Stephens NSW Australia, 06 December 2010 - 10 December 2010
2010
Conference Posters
add
Ho T; Cunningham AM; Lindholm L; Li Y; Russell PJ; Khatri A, 2005, 'Promise of BLCA-38 as a targeting antibody for tissue specific gene delivery to prostate cancer', Melbourne, AUSTRALIA, Vol. 7, pp. 1130 - 1130, presented at 4th Meeting of the Australasian Gene Therapy Society, Melbourne, AUSTRALIA, 27 April 2005 - 29 April 2005, http://dx.doi.org/10.1002/jgm.808
2005
Theses / Dissertations
add
Li Y, 2000, A study of human mast cell origin and differentiation
2000

1. Overseas Postgraduate Research Scholarship (OPRS), UNSW, Australia (1996-1999)

2. Nominee of Young Researcher of Year 2002 in Cure Cancer Australia Foundation (2002)

3. New Investigator Award, US army Defence of Department, USA (2003)

4. Travel grant Award, Prostate Cancer Foundation of Australia (2004)

5. Travel Grant Award, 18th Asia Pacific Cancer Conference, South Korea (2005)

6. Infrastructure Grant Award, Cancer Institute of NSW, Australia (2005)

7. ORIA Research Grant Award, the Ophthalmic Research Institute of Australia (2006)

8. The Best Presentation Award, 4th International Symposium on Targeted Anticancer Therapies 2006, the Netherlands (2006)

9. ARC-Linkage Grant Award, Australian Research Council, Australia (2007)

10.  Early Career Development Fellowship, Cancer Institute NSW, Australia (2007)

11. NHMRC Career Development Award, Australia (2009)

12. UNSW Golden Star Award, Australia (2009)

13. Cancer Research Honorary Award, 20th Asia Pacific Cancer Conference (APCC), Japan (2009)

14. NHMRC Achievement Award, Australia (2010)

15. St George Clinical School Research Excellence Award, UNSW, Australia (2010)

16. St George Medical Foundation-Interim Support Grant Award, St George Hospital (2010)

17. ARC-Linkage Grant Award, ARC, Australia (2010)

18. ARC-Linkage Grant Award, ARC, Australia (2011)

19. Overseas distinguished biomedical research expert, Henan Health Board, China (2016) 

1. Yong Li. Control of micrometastatic prostate cancer using multiple alpha targeted therapy. New Investigator Award. 2004-2007. 300,000 $. US army Defense of Department, USA (W81XWH-04-1-004).

2. Pamela Russell, Yong Li et al. Tissue microarrayer to enable pathological studies of cancer. CINSW equipment grant. 2006-2007. 125,000 $. CINSW.

3. Yong Li, Mark Willcox, Paul Cozzi, Pamela J Russell, Bard Walsh, Zhengjun Zhao. Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis. ARC-linkage grant. 2007-2010. 150,000 $. ARC (LP0774951).

4. Yong Li. Identification of novel urinary biomarkers for prostate cancer. UNSW Gold Star Award. 2009. 40,000 $. UNSW (630586).

5. Yong Li. Using proteomic approaches to identify novel biomarkers in tear and serum to improve diagnosis and monitor progression in prostate cancer. NSW Cancer Institute Career Development Fellowship.  2007-2010. 572,000$. Cancer Institute NSW (06/CEF/1-17).

6. Yong Li, Paul Cozzi. CD44 and CD147 in prostate cancer metastasis and chemoresistance. St George Medical Research Foundation. 2010. 40,000 $.

7. Yong Li, John Kearsley. Investigation of effects of combination therapy with anti-MUC1 antibody and docetaxel on human ovarian cancer. St George Trust Fund. 2010-2012. 120,000 $. Donation.

8.  Yong Li, Paul Cozzi, Mark Willcox, Brad Walsh. Proteomic study of urine to discover novel biomarkers for human prostate cancer. ARC-linkage grant, 2010-2013. 150,000 $. (ARCLP110100384).

9. Yong Li, Peter Graham, Brad Walsh. Proteomic study of tears to discover novel biomarkers for human breast cancer. ARC-linkage grant. 2011-2014. 163,940 $. ARC (LP110200467).

10. Yong  Li.  Identification of novel biomarkers in urine to improve diagnosis and monitor progression in prostate cancer. NHMRC Career Development Fellowship. 2010-2014. 417,000 $. NHMRC (630664).

11. Michael Grimm, Beng Chong, Steven Krilis, David Morris and Yong Li (CIE). Tuttnauer Autoclave, Step One Plus 96 well Auantitative PCR Machine, AKTA Avant 150 FPLC System, Direct Detect Spectrometer. 2014. 353,190 $. Major Research Equipment and Infrastructure Initiative grant, UNSW.

12. Jingli Hao, Yong Li , Valeri Wasinger, Peter Graham. Using proteomic approaches to identify novel biomarkers associated with prostate cancer radioresistance in in vivo animal models. New Investigator Award. 2014. 35,000 AU$. St George and Sutherland Medical Research Foundation.

13. Michael Grimm, Beng Chong, Steven Krilis, David Morris and Yong Li (CIE). FACSAria III cell sorter. 2015. 455,000 $. Major Research Equipment and Infrastructure Initiative grant, UNSW.

14. Yong Li. Investigation of cancer stem cells in prostate cancer chemo-/radioresistance.  Prostate and Breast Cancer Foundation. 2013-2015. 40,000$.

15. Richard Lock, Maria Kavallaris, Jason Wong, Anthony Don, Belamy Cheung, Nikki Verrills, Yong Li, Nigel Turner.  A Shared Mass Spectrometry Facility for Discovery and Quantitative Cancer

Research, Proteomics and Lipidomics. CINSW equipment grant (2016/REG006).100,000$.

16. Michael Grimm, Beng Chong, Yong Li (CIC), David Morris and Emad E. Acquisition of a Nikon A1+ Confocal Microscope. 2016. 448,180 $. Major Research Equipment and Infrastructure Initiative grant, UNSW.

17. Peng G, Kwok CY, Ladouceur F, Bartom M, LI Y et al. High Sensitivity Single-Photon Spectroscopy System (SPSS). 2016.  64,750 $. Major Research Equipment and Infrastructure Initiative grant, UNSW.

18. Yong Li, Ying Zhu, Peter Reece, Chee Khoon Lee, Raymond Wong. Combining nanoplasmonic profiling with machine learning for non-invasive early detection of ovarian cancer using plasma exosomes. 2020-2021 (GA-2019-13). 134,026$. Ovarian Cancer Research Foundation (OCRF).

19. Ying Zhu, Yong Li, Phoebe Phillips, Peter J. Reece. Multiparameter analysis of exosomes for non-invasive early detection of pancreatic cancer using a point-of-care nanoplasmonic sensor. 2020-2021. $96,033.30. Avner Pancreatic Cancer Foundation Innovation Grants.